In this study, we presented a novel trispecific NK cell-engaging antibody B7-H3xTIGITxCD16, which can simultaneously activate NK cells through CD16 binding, block the inhibiting NK checkpoint molecule TIGIT, and redirect NK cells towards B7-H3-positive tumor cells. This evidence concerns the gene FCGR3A and neoplasm.